SL
BCAX

Siren LLC’s Bicara Therapeutics BCAX Stock Holding History

Siren LLC’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$115M Buy
5,802,970
+586,001
+11% +$10.1M 3.2% 7
2025
Q4 		$87.8M Hold
5,216,969
– – 2.62% 8
2025
Q3 		$82.4M Hold
5,216,969
– – 3.22% 5
2025
Q2 		$48.5M Buy
5,216,969
+1,949,886
+60% +$23.2M 2.51% 6
2025
Q1 		$42.6M Sell
3,267,083
-5,744
-0.2% -$76.3K 2.4% 11
2024
Q4 		$57M Buy
3,272,827
+200,000
+7% +$4.16M 2.52% 7
2024
Q3 		$78.3M Buy
+3,072,827
New +$78.4M 3.91% 4

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $173M AUM

Siren LLC's BCAX Position: Q1 2026 in Review

Siren LLC increased its Bicara Therapeutics (BCAX) stake by 11% in Q1 2026, buying an estimated $10.1M and bringing the position to 5,802,970 shares worth $115M. The position accounts for 3.2% of the portfolio, ranked #7.

Siren LLC first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Siren LLC held 5,802,970 shares of Bicara Therapeutics worth $115M as of Q1 2026.
  • Siren LLC bought 586,001 Bicara Therapeutics shares in Q1 2026, an estimated $10.1M.
  • Bicara Therapeutics made up 3.2% of Siren LLC's portfolio in Q1 2026, its #7 holding.
  • Siren LLC first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Siren LLC's 13F filing for Q1 2026, filed 14 May 2026.